An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

Trial Details

NCT ID

NCT07222267

Phase

PHASE1

Sponsor

BeOne Medicines

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

• BG-75202
• CDK4 Inhibitor
• Estrogen Receptor Antagonist
• Aromatase Inhibitor

Locations (sample)

• Birmingham, Alabama, United States|33.52066,-86.80249
• New Haven, Connecticut, United States|41.30815,-72.92816
• St Louis, Missouri, United States|38.62727,-90.19789
• Austin, Texas, United States|30.26715,-97.74306
• Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

• Part 1A: Participants with histologically or cytologically confirmed advanced, metastatic breast cancer and other solid tumors who have exhausted, …
• Part 1B and Part 2A: Participants with advanced breast cancer with 1 to 3 prior lines of systemic therapy in the metastatic setting. Prior lines in…
• Parts 2B and 2C: Participants with advanced breast cancer enrolled in regions where cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are not approve…
• Participants with breast cancer must have histologically or cytologically confirmed advanced breast cancer at the time of most recent testing, base…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.